OncoMatch/Clinical Trials/NCT03886311
Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
Is NCT03886311 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Talimogene Laherparepvec 100000000 PFU/1 ML and Nivolumab IV Soln 100 MG/10ML for sarcoma.
Treatment: Talimogene Laherparepvec 100000000 PFU/1 ML · Nivolumab IV Soln 100 MG/10ML · Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution — This is a Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin as first, second or third line therapy for advanced sarcoma, including desmoid tumor and chordoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: oncolytic virus (talimogene laherparepvec)
Previous treatment with TALIMOGENE LAHERPAREPVEC or any other oncolytic virus
Cannot have received: immunosuppressive therapy
receiving systemic immunosuppressive therapy (> 2 weeks) including oral steroid doses > 10 mg/day of prednisone or equivalent within 7 days prior to study treatment
Cannot have received: chemotherapy
Prior immunosuppressive, chemotherapy, radiotherapy (in which the field encompassed a planned injection site), biological cancer therapy, or major surgery within 28 days prior to study treatment or has not recovered to CTCAE grade 1 or better from adverse event due to cancer therapy administered more than 28 days prior to study treatment
Cannot have received: radiotherapy
Exception: if the field encompassed a planned injection site
Prior immunosuppressive, chemotherapy, radiotherapy (in which the field encompassed a planned injection site), biological cancer therapy, or major surgery within 28 days prior to study treatment or has not recovered to CTCAE grade 1 or better from adverse event due to cancer therapy administered more than 28 days prior to study treatment
Cannot have received: biological cancer therapy
Prior immunosuppressive, chemotherapy, radiotherapy (in which the field encompassed a planned injection site), biological cancer therapy, or major surgery within 28 days prior to study treatment or has not recovered to CTCAE grade 1 or better from adverse event due to cancer therapy administered more than 28 days prior to study treatment
Cannot have received: major surgery
Prior immunosuppressive, chemotherapy, radiotherapy (in which the field encompassed a planned injection site), biological cancer therapy, or major surgery within 28 days prior to study treatment or has not recovered to CTCAE grade 1 or better from adverse event due to cancer therapy administered more than 28 days prior to study treatment
Cannot have received: radiotherapy
Exception: if the field does not overlap the injection sites
Prior radiotherapy in which the field does not overlap the injection sites or nonimmunosuppressive targeted therapy within 14 days prior to study treatment or has not recovered to CTCAE grade 1 or better from adverse event due to cancer therapy administered more than 14 days prior to study treatment
Cannot have received: nonimmunosuppressive targeted therapy
Prior radiotherapy in which the field does not overlap the injection sites or nonimmunosuppressive targeted therapy within 14 days prior to study treatment or has not recovered to CTCAE grade 1 or better from adverse event due to cancer therapy administered more than 14 days prior to study treatment
Lab requirements
Blood counts
ANC >1500/μL; Platelet count >100,000/μL; Hemoglobin >9.0 g/dL
Kidney function
Creatinine <1.5x ULN
Liver function
Bilirubin <1.5x ULN (except Gilbert Syndrome <3.0x ULN); AST, ALT, alk phos <2.5x ULN (<5x ULN if liver metastases present)
Acceptable liver function: Bilirubin <1.5x ULN (except subjects with Gilbert Syndrome who must have a total bilirubin level < 3.0 ULN); AST (SGOT), ALT (SGPT) and alk phos < 2.5 x ULN (< 5 x ULN if liver metastases present) Acceptable renal function: Creatinine < 1.5 times ULN Acceptable hematologic status: ANC >1500 cells/μL or greater; Platelet count >100,000/μL or greater; Hemoglobin > 9.0 g/dL or greater
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sarcoma Oncology Center · Santa Monica, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify